| 1 |
34158245 | A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer. | 2022 Jan |
2 |
| 2 |
35066605 | The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC. | 2022 Jan 23 |
2 |
| 3 |
24606768 | Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. | 2014 Mar 7 |
3 |
| 4 |
22331954 | First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. | 2012 Mar 20 |
2 |
| 5 |
22336056 | Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. | 2012 Aug |
1 |
| 6 |
23022045 | An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. | 2012 Dec |
4 |
| 7 |
20339913 | Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. | 2010 May |
1 |
| 8 |
20652398 | Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. | 2010 Sep |
1 |